Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

70.51USD
13 Sep 2019
Change (% chg)

$-0.32 (-0.45%)
Prev Close
$70.83
Open
$71.30
Day's High
$71.51
Day's Low
$70.48
Volume
1,843,967
Avg. Vol
2,198,489
52-wk High
$96.60
52-wk Low
$62.68

Latest Key Developments (Source: Significant Developments)

Abbvie Sets Quarterly Cash Dividend Of $1.07 Per Share
Friday, 6 Sep 2019 

Sept 6 (Reuters) - Abbvie Inc ::SETS QUARTERLY CASH DIVIDEND OF $1.07PER SHARE.  Full Article

Idera Pharma Announces Immuno-Oncology Clinical Research Collaboration With Abbvie
Wednesday, 4 Sep 2019 

Sept 4 (Reuters) - Idera Pharmaceuticals Inc ::IDERA PHARMACEUTICALS ANNOUNCES IMMUNO-ONCOLOGY CLINICAL RESEARCH COLLABORATION WITH ABBVIE.IDERA PHARMACEUTICALS INC - ENTERED INTO AN IMMUNO-ONCOLOGY CLINICAL RESEARCH COLLABORATION WITH ABBVIE.IDERA PHARMACEUTICALS INC - PHASE 1B TO DETERMINE SAFETY OF COMBINATIONS OF ABBV-368 PLUS TILSOTOLIMOD IN SUBJECTS WITH RECURRENT OR METASTATIC HNSCC.IDERA PHARMACEUTICALS INC - STUDY WILL TEST THREE SEPARATE TREATMENT ARMS.IDERA PHARMACEUTICALS INC - IDERA WILL PROVIDE CLINICAL TRIAL SUPPLY OF TILSOTOLIMOD TO ABBVIE AND ABBVIE WILL BE RESPONSIBLE FOR CONDUCT OF STUDY.  Full Article

Abbvie Receives FDA Approval Of Rinvoq (Upadacitinib) For Treatment Of Moderate To Severe Rheumatoid Arthritis
Friday, 16 Aug 2019 

Aug 16 (Reuters) - Abbvie Inc ::ABBVIE RECEIVES FDA APPROVAL OF RINVOQ™ (UPADACITINIB), AN ORAL JAK INHIBITOR FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS.ABBVIE INC - RINVOQ IS EXPECTED TO BE AVAILABLE IN U.S. IN LATE AUGUST 2019.  Full Article

FDA Approves Abbvie's Rinvoq (Upadacitinib) For Arthritis Treatment
Friday, 16 Aug 2019 

Aug 16 (Reuters) - U.S. Food and Drug Administration::FDA - APPROVES NDA FOR ABBVIE'S RINVOQ (UPADACITINIB) FOR TREATMENT OF RHEUMATOID ARTHRITIS.FDA SAYS ABBVIE'S RINVOQ (UPADACITINIB) COMES WITH A BOXED WARNING.FDA SAYS ABBVIE'S RINVOQ (UPADACITINIB) COMES WITH A BOXED WARNING ABOUT SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS.  Full Article

Allergan Reports Q2 Loss Per Share of $5.37
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Allergan Plc ::ALLERGAN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 GAAP LOSS PER SHARE $5.37.Q2 EARNINGS PER SHARE ESTIMATE $4.34 -- REFINITIV IBES DATA.RAISES GUIDANCE FOR FULL-YEAR 2019 NET REVENUE.REAFFIRMS GUIDANCE FOR FULL-YEAR 2019 PERFORMANCE NET INCOME PER SHARE.Q2 REVENUE FELL 0.8 PERCENT TO $4.09 BILLION.QTRLY NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $4.38.RESTASIS NET REVENUE IN Q2 2019 WERE $310.9 MILLION, A DECREASE OF 2.3 PERCENT.SEES 2019 TOTAL NET REVENUES $15.425 BILLION TO $15.625 BILLION.SEES 2019 LOSS PER SHARE OF MORE THAN $12.03.SEES 2019 NON-GAAP TOTAL NET REVENUE OF $15.4 BILLION - $15.6 BILLION.DUE TO PROPOSED ACQUISITION OF ALLERGAN BY ABBVIE, ALLERGAN IS NOT HOSTING A CONFERENCE CALL TO DISCUSS ITS Q2 RESULTS.FY2019 EARNINGS PER SHARE VIEW $16.72, REVENUE VIEW $15.34 BILLION -- REFINITIV IBES DATA.Q2 2019 GAAP REVENUES AND EXPENSES IMPACTED BY VOLUNTARY GLOBAL RECALL OF BIOCELL TEXTURED BREAST IMPLANTS.RECORDED TOTAL PRE-TAX IMPAIRMENT CHARGES OF $1.65 BILLION FOR QUARTER.TOTAL PRE-TAX IMPAIRMENT CHARGES FOR QUARTER INCLUDES GOODWILL IMPAIRMENT OF $1.09 BILLION IN GENERAL MEDICINE REPORTING UNIT.  Full Article

Allergan Reports Second Quarter 2019 Financial Results
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Allergan Plc ::ALLERGAN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 GAAP LOSS PER SHARE $5.37.Q2 EARNINGS PER SHARE ESTIMATE $4.34 -- REFINITIV IBES DATA.RAISES GUIDANCE FOR FULL-YEAR 2019 NET REVENUE.REAFFIRMS GUIDANCE FOR FULL-YEAR 2019 PERFORMANCE NET INCOME PER SHARE.Q2 REVENUE FELL 0.8 PERCENT TO $4.09 BILLION.QTRLY NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $4.38.RESTASIS NET REVENUE IN Q2 2019 WERE $310.9 MILLION, A DECREASE OF 2.3 PERCENT.SEES 2019 TOTAL NET REVENUES $15.425 BILLION TO $15.625 BILLION.SEES 2019 LOSS PER SHARE OF MORE THAN $12.03.SEES NON-GAAP TOTAL NET REVENUE OF $15.4 BILLION - $15.6 BILLION.DUE TO PROPOSED ACQUISITION OF ALLERGAN BY ABBVIE, ALLERGAN IS NOT HOSTING A CONFERENCE CALL TO DISCUSS ITS Q2 RESULTS.2019 GAAP REVENUES AND EXPENSES IMPACTED BY VOLUNTARY GLOBAL RECALL OF BIOCELL TEXTURED BREAST IMPLANTS.FY2019 EARNINGS PER SHARE VIEW $16.72, REVENUE VIEW $15.34 BILLION -- REFINITIV IBES DATA.  Full Article

AbbVie Submits New Drug Application To U.S. FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women
Monday, 5 Aug 2019 

Aug 5 (Reuters) - AbbVie Inc ::ABBVIE SUBMITS NEW DRUG APPLICATION TO US FDA FOR INVESTIGATIONAL ELAGOLIX FOR MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS IN WOMEN.ABBVIE INC - NEW DRUG APPLICATION IS SUPPORTED BY DATA FROM PIVOTAL PHASE 3 STUDIES OF NEARLY 800 PATIENTS.  Full Article

AbbVie'S Director Roxanne Austin Reports Open Market Purchase Of 30,000 Shares At Average Price Of $66.02 Per Share
Saturday, 3 Aug 2019 

Aug 2 (Reuters) - AbbVie Inc ::ABBVIE INC SAYS DIRECTOR ROXANNE AUSTIN REPORTS OPEN MARKET PURCHASE OF 30,000 SHARES AT AVERAGE PRICE OF $66.02PER SHARE ON JULY 31 - SEC FILING.ABBVIE INC SAYS DIRECTOR ROXANNE AUSTIN REPORTS OPEN MARKET PURCHASE OF 25,000 SHARES AT AVERAGE PRICE OF $65.66PER SHARE ON AUGUST 1.  Full Article

Abbvie Reports Qtrly EPS Of $0.49
Friday, 26 Jul 2019 

July 26 (Reuters) - AbbVie Inc ::ABBVIE QTRLY GAAP EARNINGS PER SHARE $0.49; QTRLY ADJUSTED EARNINGS PER SHARE $2.26.QTRLY NET REVENUE $8.26 BILLION VERSUS $8.28 BILLION.SAYS IS RAISING REVENUE AND ADJUSTED EPS GUIDANCE FOR 2019.Q2 EARNINGS PER SHARE VIEW $2.21, REVENUE VIEW $8.10 BILLION -- REFINITIV IBES DATA.UPDATES 2019 GAAP EARNINGS PER SHARE GUIDANCE RANGE FROM $7.26 TO $7.36 TO $5.69 TO $5.79.FY2019 EARNINGS PER SHARE VIEW $8.82 -- REFINITIV IBES DATA.RAISES 2019 ADJUSTED EARNINGS PER SHARE GUIDANCE RANGE FROM $8.73 TO $8.83 TO $8.82 TO $8.92.QTRLY GLOBAL HUMIRA NET REVENUE OF $4.87 BILLION, DOWN 6.1% ON A REPORTED BASIS.QTRLY GLOBAL IMBRUVICA NET REVENUE $1,099 MILLION, UP 29.3%.IN U.S., QTRLY HUMIRA NET REVENUE OF $3.79 BILLION, UP 7.7%.INTERNATIONALLY, Q2 HUMIRA NET REVENUE OF $1.08 BILLION, DOWN 35.2% ON REPORTED BASIS, OR 31% OPERATIONALLY, DUE TO BIOSIMILAR COMPETITION.IN Q2 RECORDED A $2.3 BILLION INCREASE IN FAIR VALUE OF CONTINGENT CONSIDERATION RELATED TO SKYRIZI FUTURE MILESTONES, ROYALTY PAYMENTS.QTRLY TOTAL SKYRIZI NET REVENUE $48 MILLION.  Full Article

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Empliciti Plus Pomalidomide And Low-Dose Dexamethasone
Friday, 26 Jul 2019 

July 26 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF EMPLICITI (ELOTUZUMAB) PLUS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA.BRISTOL-MYERS SQUIBB - CO & ABBVIE ARE TOGETHER DEVELOPING EMPLICITI, WITH CO SOLELY RESPONSIBLE FOR COMMERCIAL ACTIVITIES.  Full Article

Photo

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

WASHINGTON About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's planned $63 billion purchase of Botox maker Allergan Plc .